金龙羽(002882) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥1,010,206,955.41, a decrease of 0.68% compared to the previous quarter and a decline of 9.72% year-on-year[4]. - The net profit attributable to shareholders for Q3 2023 was ¥53,288,808.56, down 14.33% from the previous quarter and down 4.07% year-on-year[4]. - The net profit after deducting non-recurring gains and losses was ¥51,428,705.03, a decrease of 15.65% quarter-on-quarter and 7.02% year-on-year[4]. - The basic earnings per share for Q3 2023 was ¥0.1231, reflecting a 14.34% decrease compared to the previous quarter and a 4.07% decline year-on-year[4]. - The company reported a total profit of ¥226,791,952.73 for Q3 2023, down from ¥240,684,022.41 in Q3 2022, a decrease of 5.8%[26]. Assets and Liabilities - The total assets at the end of Q3 2023 amounted to ¥3,045,748,606.39, representing an increase of 8.80% compared to the end of the previous year[4]. - The equity attributable to shareholders at the end of Q3 2023 was ¥2,104,374,754.45, an increase of 4.63% from the end of the previous year[4]. - The company's total liabilities as of Q3 2023 were ¥941,373,851.94, an increase from ¥788,800,493.37 in the previous year[16]. - The total inventory as of Q3 2023 was ¥729,082,088.65, up from ¥598,179,332.40 in the previous year[13]. Cash Flow - The net cash flow from operating activities was negative at -¥271,473,580.58, indicating a significant decline of 731.95% year-on-year[4]. - Cash inflow from operating activities totaled 2,776,908,964.83 CNY, down from 3,225,234,214.74 CNY in the previous year[34]. - Cash outflow from operating activities was 3,048,382,545.41 CNY, compared to 3,182,275,936.97 CNY in the previous year[34]. - The net cash flow from investing activities was -101,128,292.69 CNY, a decrease of 120.81% compared to the previous year[39]. - The net cash flow from financing activities was 178,073,026.82 CNY, an increase of 894.77% compared to the previous year[39]. - Total cash and cash equivalents decreased by 193,752,851.12 CNY during the reporting period[39]. - The ending balance of cash and cash equivalents was 197,981,671.50 CNY, down from 263,179,920.75 CNY in the previous year[34]. Expenses - The company reported a total operating cost of ¥2,555,785,670.23 for the year-to-date, down from ¥2,851,499,491.56 in the previous year[16]. - Financial expenses decreased by 56.27% to ¥10,824,180.39 in Q3 2023 from ¥24,749,569.69 in Q3 2022, attributed to reduced financing scale and costs[19]. - Research and development expenses increased to ¥17,899,265.77 in Q3 2023 from ¥14,408,444.81 in Q3 2022, indicating a focus on innovation[26]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 34,225[40]. - The largest shareholder, Zheng Youshui, holds 56.83% of the shares, totaling 246,000,000 shares[40]. Strategic Initiatives - The company plans to engage in accounts receivable factoring with a maximum amount of RMB 400 million within one year[43]. - The company intends to use up to RMB 400 million of idle funds for short-term financial products with high safety and liquidity[43]. - The company will continue hedging operations with a maximum trading margin of RMB 30 million and a maximum contract value of RMB 250 million[43]. - The company has completed testing and improvement of semi-solid battery materials and processes, with ongoing development of solid electrolyte and anode materials[45]. - The company has been granted 15 national invention patents related to its research and development efforts[46]. Other Income - The non-operating income for the current period amounts to RMB 1,860,103.53, with significant contributions from carbon emission quota transfers and litigation compensation[49]. - The total government subsidies recognized in the current period amount to RMB 123,621.03, primarily from intellectual property financing and tax incentives[49]. - The company has reported a total of RMB 212,706.02 in non-current asset disposal gains during the reporting period[49].